3D Medicines (HKSE:01244) EV-to-EBIT : -1.42 (As of Jun. 05, 2024)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 3D Medicines's Enterprise Value is HK$859.9 Mil. 3D Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-606.7 Mil. Therefore, 3D Medicines's EV-to-EBIT for today is -1.42.

The historical rank and industry rank for 3D Medicines's EV-to-EBIT or its related term are showing as below:

HKSE:01244' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.53 Med: -1.08 Max: 0.49
Current: -1.42

During the past 4 years, the highest EV-to-EBIT of 3D Medicines was 0.49. The lowest was -5.53. And the median was -1.08.

HKSE:01244's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs HKSE:01244: -1.42

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. 3D Medicines's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,119.3 Mil. 3D Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-606.7 Mil. 3D Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -54.20%.

3D Medicines EV-to-EBIT Historical Data

The historical data trend for 3D Medicines's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines EV-to-EBIT Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-8.50

-1.84

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-8.50	-	-1.84

Competitive Comparison of 3D Medicines's EV-to-EBIT

For the Biotechnology subindustry, 3D Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 3D Medicines's EV-to-EBIT falls into.

3D Medicines EV-to-EBIT Calculation

3D Medicines's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	859.946	/	-606.713
	=	-1.42

3D Medicines's current Enterprise Value is HK$859.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-606.7 Mil.

3D Medicines (HKSE:01244) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

3D Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-606.713	/	1119.32848
	=	-54.20 %

3D Medicines's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,119.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-606.7 Mil.

3D Medicines EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of 3D Medicines's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines